Business Industry Reports Research has recently announced a report on Global Atenolol Tablets Market based on the Healthcare Industry. The Atenolol Tablets Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Overview of Global Atenolol Tablets Market:
Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This medication is also used to treat chest pain (angina) and to improve survival after a heart attack. Atenolol belongs to a class of drugs known as beta-blockers.
The report contains a complete product overview and its scope in the market to define the key terms and provide the clients a holistic idea of the market and its tendency. It comprehensively evaluates the global Atenolol Tablets market with different perspectives for the purpose of providing a detailed, informative, and accurate analysis of regional growth, competition, market segmentation, and other important aspects.
Growth in the historic period resulted from economic growth in emerging markets, the rise in awareness of the benefits and developed nations towards Atenolol Tablets costs and an increase in the number of medicine for treatment of high blood pressure by preventing heart attacks.
Product Type Segmentation:
The Atenolol Tablets market have different product type such as 25mg, 50mg and 100mg. Atenolol Tablets market product type gives medicinal treatment for the high blood pressure patient for preventing heart attack and kidney problems.
Increasing instances across various sectors such as Hypertension, Angina and Arrhythmias are raising the need of healthcare institutes, thereby raising the demand for Atenolol Tablets market. This help in the profitable growth of the Global Atenolol Tablets market in upcoming year.
Segmentation by Regions:
The Atenolol Tablets market in North America has created medical treatment for high blood pressure to help preventing the heart patients in the world. It was followed by Western Europe, China, Japan, Southeast Asia, India and Central & South America regions. Asia Pacific is expected to record higher growth rate in Atenolol Tablets Market during the forecast year.
Top Leading Key Manufacturers are: AstraZeneca, ACETO, Aurobindo Pharma, Sandoz, Mylan, Sun Pharmaceutical, Teva, Zydus Pharmaceuticals, Unique Pharmaceuticals, Ipca Laboratories, Intas Pharmaceuticals. New product launches and continuous technological innovations are the key strategies adopted by the major players.
Top Industry News:
Lynparza recommended for approval in EU by CHMP for BRCA-mutated metastatic pancreatic cancer on 01 June, 2020 — AstraZeneca and MSD Inc., Kenilworth, N.J., US today announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line maintenance treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the Phase III POLO trial, which were published in The New England Journal of Medicine.
The trial demonstrated that Lynparza nearly doubled the time patients with gBRCAm metastatic pancreatic cancer lived without disease progression or death to a median of 7.4 months versus 3.8 months on placebo. The safety and tolerability profile of Lynparza in the POLO trial was consistent with previous trials.
José Baselga, Executive Vice President, Oncology R&D, said: “Patients with advanced pancreatic cancer have seen limited treatment advances over the last few decades. We are now one step closer to bringing the first targeted medicine to certain biomarker-selected patients with advanced pancreatic cancer in the EU.”
Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief Medical Officer, MSD Research Laboratories, said: “A pancreatic cancer diagnosis is devastating, and we are committed to research that aims to change the prognosis for patients. The POLO Phase III trial demonstrated that treatment with Lynparza extended time without disease progression in certain patients with advanced pancreatic cancer – we are hopeful that we will be able to bring this treatment to patients in the EU soon.”
Major Points in Table of Contents:
1 Atenolol Tablets Product Definition
2 Global Atenolol Tablets Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Atenolol Tablets Shipments
2.2 Global Manufacturer Atenolol Tablets Business Revenue
2.3 Global Atenolol Tablets Market Overview
3 Manufacturer Atenolol Tablets Business Introduction
3.1 AstraZeneca Atenolol Tablets Business Introduction
3.1.1 AstraZeneca Atenolol Tablets Shipments, Price, Revenue and Gross profit 2020-2024
3.1.2 AstraZeneca Atenolol Tablets Business Distribution by Region
3.1.3 AstraZeneca Interview Record
3.1.4 AstraZeneca Atenolol Tablets Business Profile
3.1.5 AstraZeneca Atenolol Tablets Product Specification
3.2 ACETO Atenolol Tablets Business Introduction
3.2.1 ACETO Atenolol Tablets Shipments, Price, Revenue and Gross profit 2020-2024
3.2.2 ACETO Atenolol Tablets Business Distribution by Region
3.2.3 Interview Record
3.2.4 ACETO Atenolol Tablets Business Overview
3.2.5 ACETO Atenolol Tablets Product Specification
3.3 Aurobindo Pharma Atenolol Tablets Business Introduction
3.3.1 Aurobindo Pharma Atenolol Tablets Shipments, Price, Revenue and Gross profit 2020-2024
3.3.2 Aurobindo Pharma Atenolol Tablets Business Distribution by Region
3.3.3 Interview Record
3.3.4 Aurobindo Pharma Atenolol Tablets Business Overview
3.3.5 Aurobindo Pharma Atenolol Tablets Product Specification
3.4 Sandoz Atenolol Tablets Business Introduction
3.5 Mylan Atenolol Tablets Business Introduction
3.6 Sun Pharmaceutical Atenolol Tablets Business Introduction